Renowned Cardiologist and Innovator Brings Unparalleled Expertise to Story Health and Fuels Mission of Transforming Care for Americans with Heart Failure SAN JOSE, Calif.–(BUSINESS WIRE)–Story Health, a health technology and services company that extends specialty care to patients’ homes, today announced the appointment of Dr. Andrew Sauer to its Board of Advisors. Dr. Sauer is … [Read more…]
The Ovation Research Network is the latest addition to the NIH’s RADx Tech Variant Task Force, providing near-immediate tracking of SARS-CoV-2 variants CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cloud-based molecular Laboratory Information Management Software (LIMS) leader Ovation today announced the formal launch of the Ovation Research Network. The Ovation Research Network is a platform of clinical laboratories who use … [Read more…]
SANFORD, Fla.–(BUSINESS WIRE)–RepScrubs LLC, a leader in perioperative vendor management, has launched a new datacentric compliance platform to simplify vendor credentialing compliance, accountability, and security for hospitals, health systems and surgery centers. Healthcare organizations often have no formal process for documenting, managing and reconciling perioperative vendor visits. RepScrubs’ closed-loop system automates the process to ensure … [Read more…]
Fund brings sustainable, mixed-use developments to New England communities BOSTON–(BUSINESS WIRE)–UnitedHealth Group (NYSE: UNH) today announced a $25 million commitment to the Healthy Neighborhoods Equity Fund II (HNEF II). The fund, launched by Conservation Law Foundation (CLF) and Massachusetts Housing Investment Corporation (MHIC), was created to finance inclusive mixed-use developments near public transportation that offer … [Read more…]
Reproxalap Statistically Superior to Vehicle for Both Primary Endpoints of Ocular Redness (P=0.0004) and Schirmer Test (P=0.0005) Schirmer Test ≥10mm Responder Analysis Multiplicity-Controlled Secondary Endpoint Achieved (P=0.0361) Secondary Endpoints Achieved for All Symptoms Assessed: Dryness (P=0.0068), Discomfort (P<0.0001), Grittiness (P=0.0001), Stinging (P=0.0001), Burning (P<0.0001), and Itching (P=0.0003) Company to Host Conference Call at 8:00 a.m. … [Read more…]
Genentech exercises second option to initiate an additional program under the 2020 collaboration agreement CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised its … [Read more…]
BOSTON–(BUSINESS WIRE)–Etiometry, a leader in clinical decision-support software for critical care, announced today that it has doubled its FDA-cleared risk analytics portfolio to four indices, further strengthening its capability to track the fundamental pathways through which patients deteriorate under intensive care. Etiometry is the only critical care AI decision-support company with four FDA-cleared algorithms. The … [Read more…]
Mental health a key indicator; 58% of adults negatively affected by pandemic INDIANAPOLIS–(BUSINESS WIRE)–Arlington, Virginia, has been named “America’s Fittest City” in the annual American Fitness Index® rankings published by the American College of Sports Medicine (ACSM) and the Elevance Health Foundation, the philanthropic arm of Elevance Health. The ACSM / Elevance Health Foundation Fitness … [Read more…]
Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 Cash and cash equivalents at May 31, 2022 were $28.8 million Full-Year 2022 … [Read more…]
STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed. As previously announced, the Phase III clinical trial was placed on clinical hold by … [Read more…]
